Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 461

Sort by

Sort Order Select

Journal Articles

HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study

Blood blood.2024026915.

https://doi.org/10.1182/blood.2024026915

Published: 2025

Includes: Supplemental data

Journal Articles

A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia

Blood blood.2024025440.

https://doi.org/10.1182/blood.2024025440

Published: 2025

Includes: Supplemental data

Journal Articles

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study

Blood (2024) 144 (21): 2237–2247.

https://doi.org/10.1182/blood.2024024493

Published: 2024

Includes: Supplemental data

Journal Articles

Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study

Franco Locatelli, Hyoung Jin Kang, Bénédicte Bruno, Virginie Gandemer, Fanny Rialland, Maura Faraci, Yoshiyuki Takahashi, Katsuyoshi Koh, Henrique Bittencourt, Grace Cleary, Christine Rosko, Xuechan Li, Annie St Pierre, Anirudh Prahallad, Cristina Diaz-de-Heredia

Blood (2024) 144 (20): 2095–2106.

https://doi.org/10.1182/blood.2023022565

Published: 2024

Includes: Supplemental data

Journal Articles

NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression

Blood (2024) 144 (19): 2002–2017.

https://doi.org/10.1182/blood.2023022050

Published: 2024

Includes: Supplemental data

Journal Articles

Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party

Donatella Baronciani, Josu de la Fuente, Jacques-Emanuel Galimard, Arnaud Dalissier, Ashrafsadat Mousavi, Akif Yesilipek, Hasan Hashem, Gulyuz Ozturk, Franco Locatelli, Ali Alahmari, Javid Gaziev, Ali Bülent Antmen, O. Alphan Kupesiz, Tunc Fisgin, Giorgio La Nasa, Arjan C. Lankester, Eugene Goussetis, Sandrine Bremathas, Emanuele Angelucci

Blood (2024) 144 (Supplement 1): 2136.

https://doi.org/10.1182/blood-2024-208421

Published: 2024

Journal Articles

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Blood (2024) 144 (Supplement 1): 310.

https://doi.org/10.1182/blood-2024-193946

Published: 2024

Journal Articles

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Blood (2024) 144 (Supplement 1): 309.

https://doi.org/10.1182/blood-2024-204943

Published: 2024

Journal Articles

Pursuing Leukemia Stem Cells Definition in Pediatric Acute Myeloid Leukemia

Maddalena Benetton, Ambra Da Ros, Alberto Peloso, Giorgia Longo, Katia Polato, Sara Perpinello, Silvia Bresolin, Claudia Tregnago, Benjamin J Huang, Soheil Meshinchi, Franco Locatelli, Martina Pigazzi

Blood (2024) 144 (Supplement 1): 640.

https://doi.org/10.1182/blood-2024-207102

Published: 2024

Journal Articles

Genetic and Functional Characterization of NUP98 -Rearranged Leukemia

Masayuki Umeda, Nicole L Michmerhuizen, Ryan Hiltenbrand, Juan M Barajas, Bright Arthur, Michael P Walsh, Guangchun Song, Jing Ma, Tamara Westover, Petri Pölönen, Cristina Mecucci, Danika Di Giacomo, Franco Locatelli, Riccardo Masetti, Salvatore Bertuccio, Martina Pigazzi, Ilaria Iacobucci, Charles G. Mullighan, Jeffery M Klco

Blood (2024) 144 (Supplement 1): 325.

https://doi.org/10.1182/blood-2024-210208

Published: 2024

Journal Articles

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Blood (2024) 144 (Supplement 1): 730.

https://doi.org/10.1182/blood-2024-201936

Published: 2024

Journal Articles

Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Blood (2024) 144 (Supplement 1): 595.

https://doi.org/10.1182/blood-2024-194713

Published: 2024

Journal Articles

Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party

Blood (2024) 144 (Supplement 1): 2184.

https://doi.org/10.1182/blood-2024-208191

Published: 2024

Journal Articles

Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party

Blood (2024) 144 (Supplement 1): 2182.

https://doi.org/10.1182/blood-2024-207029

Published: 2024

Journal Articles

Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Blood (2024) 144 (Supplement 1): 512.

https://doi.org/10.1182/blood-2024-205779

Published: 2024

Journal Articles

Outcomes of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia Given Blinatumomab As Last Consolidation Treatment before Allogeneic Hematopoietic Cell Transplantation

Blood (2024) 144 (Supplement 1): 3561.

https://doi.org/10.1182/blood-2024-207504

Published: 2024

Journal Articles

Effective Dual Targeting of PRAME and WT1 with CD33-Gated ARTEMIS® Antibody-TCR Platform in Acute Myeloid Leukemia

Melia Blankenfeld, Danielle C. Kirkey, Guangyan Xiong, Hongbing Zhang, Grace Hawkins, Isabel Lira, Cyd McKay, Christina Root, Concetta Quintarelli, Franco Locatelli, Cheng Liu, Soheil Meshinchi

Blood (2024) 144 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2024-206204

Published: 2024

Journal Articles

Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Blood (2024) 144 (Supplement 1): 4954.

https://doi.org/10.1182/blood-2024-204001

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I

Blood (2024) 144 (Supplement 1): 5079.

https://doi.org/10.1182/blood-2024-203643

Published: 2024

Journal Articles

Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study

Blood (2024) 144 (Supplement 1): 4864.

https://doi.org/10.1182/blood-2024-203358

Published: 2024

NARROW

HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study

A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study

Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study

NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Pursuing Leukemia Stem Cells Definition in Pediatric Acute Myeloid Leukemia

Genetic and Functional Characterization of NUP98 -Rearranged Leukemia

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party

Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party

Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Outcomes of Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia Given Blinatumomab As Last Consolidation Treatment before Allogeneic Hematopoietic Cell Transplantation

Effective Dual Targeting of PRAME and WT1 with CD33-Gated ARTEMIS® Antibody-TCR Platform in Acute Myeloid Leukemia

Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I

Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only